- Oral presentation
- Open Access
Development of subtype specific RealTime PCR based growth competition assay for assessing the replication fitness of drug resistant viruses of Indian HIV-1 clade C
© Hingankar et al; licensee BioMed Central Ltd. 2014
Published: 27 May 2014
The knowledge of replication fitness of drug resistant viruses is essential for designing the rational treatment regimens. We report development of HIV-1 Indian Clade C specific assay for studying the replication fitness of drug resistant viruses.
HIV-1 Subtype C molecular infectious clone pIndieC (Genebank AB023804) was used to construct two experimental vectors, pIndieC consInC RTWILD and pIndieC consInC RTSYNM, which are identical except for the presence of four synonymous nucleotides differences in Integrase. Standard curve was prepared for each vector using linear plasmid DNA template. The K103N, V106A, V106M, Y181C resistance mutations were placed in the pIndieC consInC RTWILD and replication fitness of each mutant was compared with that of wild type in a head to head growth competition assay. Virus supernatant harvested at day 0, 4, 8, 12 for RealTime quantitative PCR assessment. Relative fitness was estimated using online tool http://bis.urmc.rochester.edu/vFitness and significant differences in relative fitness between wild and mutant were determined with Mann Whitney test.
The slopes of standard curves for the vectors showed similar reaction efficiencies. Relative fitness of RTSYNM when competed with RTWILD was 1.01 demonstrating similar replication fitness and utility in competition assay. Three mutants showed decreased relative fitness compared to the wild type, with borderline significant difference in two, resulting in fitness order wild type>181C>K103N>V106M, whereas V106A mutant showed drastic decrease as almost non infectious.
The growth competition assay developed is able to accurately measure differences in replication fitness as impact of single drug resistance mutation in Reverse Transcriptase.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.